Skip to main content
  • Cataract/Anterior Segment, Comprehensive Ophthalmology, Cornea/External Disease, Glaucoma

    A weekly roundup of ophthalmic news from around the web.

    No need to take those fish oil pills if you have dry eye disease. An ancillary study of the randomized, double-blind, placebo-controlled Vitamin D and Omega-3 Trial (VITAL), VITAL-Dry Eye evaluated the role of vitamin D and marine omega-3 fatty acid supplements in incident dry eye disease (DED). Patients included in VITAL-Dry Eye were those enrolled in VITAL who had not been previously diagnosed with DED or who were not currently experiencing dry eye symptoms. Over a median of 5.3 years, there was no difference in diagnosed DED or in incident DED plus incident severe DED symptoms between those given omega-3 fatty acids (1 g/day) and those given placebo. Therefore, the authors conclude that “These results do not support recommending marine omega-3 fatty acid supplementation to reduce the incidence of DED.” JAMA Ophthalmology

    What predicts early onset of primary open-angle glaucoma? The answer is early onset of hypertension or type 2 diabetes (T2D), according to a cross-sectional study of 389 patients with primary open-angle glaucoma (POAG) seen at a single eye clinic in the United States. No significant differences in mean age at POAG diagnosis were found between patients with or without a history of migraine or sleep apnea. Clinicians seeing patients who have already been diagnosed with hypertension or T2D, or who have a family history of these conditions, may want to conduct early glaucoma screenings in these populations. Clinical Ophthalmology

    New cataract treatment system is approved by the FDA. The ALLY Adaptive Cataract Treatment System (Lensar) allows cataract surgeons to perform femtosecond laser-assisted cataract surgery in a single, sterile environment via a compact platform mounted on wheels. It uses adaptive intelligence to help optimize fragment patterns and ascertain cataract density. The ALLY system will have a limited launch in the 3rd quarter of 2022, and is expected to be in wide release in 2023. Ophthalmology Times